An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00292799|
Recruitment Status : Completed
First Posted : February 16, 2006
Last Update Posted : July 16, 2008
|Condition or disease||Intervention/treatment||Phase|
|Anovulation Obesity||Drug: Orlistat Vs Metformin||Not Applicable|
We aim to recruit 40 patients suffering from anovulatory obesity with a BMI of 30 or more. Patients will be included from all ethnic groups.
Patients will have a baseline history, clinical examination, hormonal profile (FSH/LH, fasting Insulin/glucose ratio, androgen profile, day 21 serum progesterone, serum leptin and ghrelin levels) ultrasound examination (ovarian volume and antral follicle count), including Doppler blood flow study (ovarian stromal velocity, PI, RI, SD ratio and power Doppler) Participants will then be randomised to receive either metformin or orlistat. Patients receiving orlistat will receive the standard dose of the drug as recommended in the BNF. Metformin will be given in an incremental dose starting at 1000mg per day and increased at 4 weekly intervals to 2000mg/d, depending on the occurrence of any gastrointestinal intolerance. The endocrinological and ultrasound investigations will be repeated at 4 weekly intervals. Both groups will be given a standard exercise and diet program in conjunction with medical treatment.
The clinical endpoint will be the achievement of conception, a Body Mass Index of less than 30, or completion of a 3-month course of treatment.
A randomised controlled open label clinical trial. Participants be randomised using a computer generated randomisation program available at the pharmacy of the Jessop Wing, into either one of two arms: metformin or orlistat. The randomisation will be stratified in order to achieve a homogenous distribution of PCOS and non-PCOS patients in both arms of the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women.|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||February 2008|
|Actual Study Completion Date :||February 2008|
- Outcome measures:
- 1- The occurrence of ovulation as measured by day-21 serum progesterone ( equal to or more than 30mmol/L).
- 2- Number of patients who have lost at least 5% of body weight at the end of the study.
- 3- Improvement/deterioration of clinical symptoms: hyper androgenic features, obesity and menstrual disturbances
- 4- Change in the ovarian Doppler indices.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00292799
|Sheffield Teaching Hospitals NHS Trust, Jessop Wing|
|Sheffield, United Kingdom, S10 2SF|
|Study Chair:||Professor William L Ledger, D.Phil,FRCOG||Sheffield University|
|Study Director:||Dr Mostafa Metwally||Sheffield University|
|Study Chair:||Professor TC Li||Sheffield Teaching Hospitals|